BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 22162832)

  • 1. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
    Li M; Mukasa A; Inda MM; Zhang J; Chin L; Cavenee W; Furnari F
    J Exp Med; 2011 Dec; 208(13):2657-73. PubMed ID: 22162832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro.
    Lan Q; Wang A; Cheng Y; Mukasa A; Ma J; Hong L; Yu S; Sun L; Huang Q; Purow B; Li M
    Oncotarget; 2016 Mar; 7(9):9680-91. PubMed ID: 26848767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of GBP1 predicts poor prognosis and promotes tumor growth in human glioblastoma multiforme.
    Ji X; Zhu H; Dai X; Xi Y; Sheng Y; Gao C; Liu H; Xue Y; Liu J; Shi J; Zhang Y; Chen Y; Dai X; Li M; Wang A; Dong J
    Cancer Biomark; 2019; 25(3):275-290. PubMed ID: 29991124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
    Yin D; Ogawa S; Kawamata N; Leiter A; Ham M; Li D; Doan NB; Said JW; Black KL; Phillip Koeffler H
    Oncogene; 2013 Feb; 32(9):1155-63. PubMed ID: 22580610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway.
    Yu S; Yu X; Sun L; Zheng Y; Chen L; Xu H; Jin J; Lan Q; Chen CC; Li M
    Oncogene; 2020 Jul; 39(27):5042-5055. PubMed ID: 32518375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
    Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma.
    Zhang C; Han X; Xu X; Zhou Z; Chen X; Tang Y; Cheng J; Moazzam NF; Liu F; Xu J; Peng W; Du F; Zhang B; Song Z; Zeng J; Gong A
    Cell Death Dis; 2018 May; 9(5):469. PubMed ID: 29700308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GBP5 drives malignancy of glioblastoma via the Src/ERK1/2/MMP3 pathway.
    Yu X; Jin J; Zheng Y; Zhu H; Xu H; Ma J; Lan Q; Zhuang Z; Chen CC; Li M
    Cell Death Dis; 2021 Feb; 12(2):203. PubMed ID: 33608513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion.
    Zheng Y; Yang W; Aldape K; He J; Lu Z
    J Biol Chem; 2013 Nov; 288(44):31488-95. PubMed ID: 24045955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas.
    Higgins DMO; Caliva M; Schroeder M; Carlson B; Upadhyayula PS; Milligan BD; Cheshier SH; Weissman IL; Sarkaria JN; Meyer FB; Henley JR
    BMC Cancer; 2020 Dec; 20(1):1213. PubMed ID: 33302912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis.
    Talasila KM; Soentgerath A; Euskirchen P; Rosland GV; Wang J; Huszthy PC; Prestegarden L; Skaftnesmo KO; Sakariassen PØ; Eskilsson E; Stieber D; Keunen O; Brekka N; Moen I; Nigro JM; Vintermyr OK; Lund-Johansen M; Niclou S; Mørk SJ; Enger PO; Bjerkvig R; Miletic H
    Acta Neuropathol; 2013 May; 125(5):683-98. PubMed ID: 23429996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
    Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ
    Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs involved in the EGFR pathway in glioblastoma.
    Xu B; Mei J; Ji W; Huo Z; Bian Z; Jiao J; Li X; Sun J; Shao J
    Biomed Pharmacother; 2021 Feb; 134():111115. PubMed ID: 33341046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma.
    Fang R; Chen X; Zhang S; Shi H; Ye Y; Shi H; Zou Z; Li P; Guo Q; Ma L; He C; Huang S
    Nat Commun; 2021 Jan; 12(1):177. PubMed ID: 33420027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
    Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
    Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of glycosyltransferase PomGnT1 in glioblastoma progression.
    Lan J; Guo P; Lin Y; Mao Q; Guo L; Ge J; Li X; Jiang J; Lin X; Qiu Y
    Neuro Oncol; 2015 Feb; 17(2):211-22. PubMed ID: 25085363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
    Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
    Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.
    Binder ZA; Thorne AH; Bakas S; Wileyto EP; Bilello M; Akbari H; Rathore S; Ha SM; Zhang L; Ferguson CJ; Dahiya S; Bi WL; Reardon DA; Idbaih A; Felsberg J; Hentschel B; Weller M; Bagley SJ; Morrissette JJD; Nasrallah MP; Ma J; Zanca C; Scott AM; Orellana L; Davatzikos C; Furnari FB; O'Rourke DM
    Cancer Cell; 2018 Jul; 34(1):163-177.e7. PubMed ID: 29990498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.